Does the media favor ANGO or TMO?

In the previous week, Thermo Fisher Scientific had 7 more articles in the media than AngioDynamics. MarketBeat recorded 40 mentions for Thermo Fisher Scientific and 33 mentions for AngioDynamics. Thermo Fisher Scientific's average media sentiment score of 1.15 beat AngioDynamics' score of 0.38 indicating that Thermo Fisher Scientific is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment AngioDynamics 6 Very Positive mention(s) 3 Positive mention(s) 15 Neutral mention(s) 4 Negative mention(s) 0 Very Negative mention(s) Neutral Thermo Fisher Scientific 27 Very Positive mention(s) 5 Positive mention(s) 8 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer WST or ANGO?

In the previous week, AngioDynamics had 26 more articles in the media than West Pharmaceutical Services. MarketBeat recorded 33 mentions for AngioDynamics and 7 mentions for West Pharmaceutical Services. West Pharmaceutical Services' average media sentiment score of 0.65 beat AngioDynamics' score of 0.38 indicating that West Pharmaceutical Services is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment West Pharmaceutical Services 1 Very Positive mention(s) 4 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive AngioDynamics 6 Very Positive mention(s) 3 Positive mention(s) 15 Neutral mention(s) 4 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media prefer BFLY or ANGO?

In the previous week, AngioDynamics had 13 more articles in the media than Butterfly Network. MarketBeat recorded 33 mentions for AngioDynamics and 20 mentions for Butterfly Network. AngioDynamics' average media sentiment score of 0.38 beat Butterfly Network's score of 0.27 indicating that AngioDynamics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Butterfly Network 6 Very Positive mention(s) 1 Positive mention(s) 10 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral AngioDynamics 6 Very Positive mention(s) 3 Positive mention(s) 15 Neutral mention(s) 4 Negative mention(s) 0 Very Negative mention(s) Neutral

Is ANGO or AXGN more profitable?

AngioDynamics has a net margin of -10.12% compared to AxoGen's net margin of -13.36%. AngioDynamics' return on equity of -4.43% beat AxoGen's return on equity. Company Net Margins Return on Equity Return on Assets AngioDynamics -10.12% -4.43% -2.89% AxoGen -13.36% -8.90% -6.47%

Does the media favor ANGO or AXGN?

In the previous week, AngioDynamics had 22 more articles in the media than AxoGen. MarketBeat recorded 33 mentions for AngioDynamics and 11 mentions for AxoGen. AngioDynamics' average media sentiment score of 0.38 beat AxoGen's score of 0.35 indicating that AngioDynamics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment AngioDynamics 6 Very Positive mention(s) 3 Positive mention(s) 15 Neutral mention(s) 4 Negative mention(s) 0 Very Negative mention(s) Neutral AxoGen 1 Very Positive mention(s) 1 Positive mention(s) 6 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media prefer INSP or ANGO?

In the previous week, AngioDynamics had 24 more articles in the media than Inspire Medical Systems. MarketBeat recorded 33 mentions for AngioDynamics and 9 mentions for Inspire Medical Systems. Inspire Medical Systems' average media sentiment score of 1.24 beat AngioDynamics' score of 0.38 indicating that Inspire Medical Systems is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Inspire Medical Systems 7 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive AngioDynamics 6 Very Positive mention(s) 3 Positive mention(s) 15 Neutral mention(s) 4 Negative mention(s) 0 Very Negative mention(s) Neutral

AngioDynamics (ANGO) Competitors

$11.52 +0.29 (+2.58%)

Closing price 10/9/2026 04:00 PM Eastern

Extended Trading

$11.44 -0.08 (-0.74%)

As of 10/9/2026 07:55 PM Eastern

Compare

ANGO vs. TMO, WST, BFLY, AXGN, and INSP

Should you buy AngioDynamics stock or one of its competitors? AngioDynamics's main competitors and comparable companies include Thermo Fisher Scientific (TMO), West Pharmaceutical Services (WST), Butterfly Network (BFLY), AxoGen (AXGN), and Inspire Medical Systems (INSP). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "healthcare" sector.

How does AngioDynamics compare to Thermo Fisher Scientific?

AngioDynamics (NASDAQ:ANGO) and Thermo Fisher Scientific (NYSE:TMO) are both healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their risk, earnings, profitability, dividends, analyst recommendations, valuation, media sentiment and institutional ownership.

Thermo Fisher Scientific has higher revenue and earnings than AngioDynamics. AngioDynamics is trading at a lower price-to-earnings ratio than Thermo Fisher Scientific, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
AngioDynamics	$320.17M	1.51	-$36.74M	-$0.78	N/A
Thermo Fisher Scientific	$46.34B	5.25	$6.70B	$18.59	35.41

89.4% of AngioDynamics shares are owned by institutional investors. Comparatively, 89.2% of Thermo Fisher Scientific shares are owned by institutional investors. 6.0% of AngioDynamics shares are owned by company insiders. Comparatively, 0.3% of Thermo Fisher Scientific shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

AngioDynamics currently has a consensus price target of $19.50, indicating a potential upside of 69.27%. Thermo Fisher Scientific has a consensus price target of $634.86, indicating a potential downside of 3.55%. Given AngioDynamics' higher possible upside, analysts clearly believe AngioDynamics is more favorable than Thermo Fisher Scientific.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
AngioDynamics	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.60
Thermo Fisher Scientific	2 Sell rating(s)	3 Hold rating(s)	18 Buy rating(s)	2 Strong Buy rating(s)	2.80

Thermo Fisher Scientific has a net margin of 15.04% compared to AngioDynamics' net margin of -10.12%. Thermo Fisher Scientific's return on equity of 17.09% beat AngioDynamics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
AngioDynamics	-10.12%	-4.43%	-2.89%
Thermo Fisher Scientific	15.04%	17.09%	8.12%

In the previous week, Thermo Fisher Scientific had 7 more articles in the media than AngioDynamics. MarketBeat recorded 40 mentions for Thermo Fisher Scientific and 33 mentions for AngioDynamics. Thermo Fisher Scientific's average media sentiment score of 1.15 beat AngioDynamics' score of 0.38 indicating that Thermo Fisher Scientific is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
AngioDynamics	6 Very Positive mention(s)	3 Positive mention(s)	15 Neutral mention(s)	4 Negative mention(s)	0 Very Negative mention(s)	Neutral
Thermo Fisher Scientific	27 Very Positive mention(s)	5 Positive mention(s)	8 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

AngioDynamics has a beta of 0.3, meaning that its stock price is 70% less volatile than the broader market. Comparatively, Thermo Fisher Scientific has a beta of 0.87, meaning that its stock price is 13% less volatile than the broader market.

Summary

Thermo Fisher Scientific beats AngioDynamics on 14 of the 17 factors compared between the two stocks.

How does AngioDynamics compare to West Pharmaceutical Services?

West Pharmaceutical Services (NYSE:WST) and AngioDynamics (NASDAQ:ANGO) are both healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, dividends, earnings, media sentiment, analyst recommendations, profitability, institutional ownership and risk.

West Pharmaceutical Services currently has a consensus target price of $385.33, suggesting a potential upside of 5.26%. AngioDynamics has a consensus target price of $19.50, suggesting a potential upside of 69.27%. Given AngioDynamics' higher possible upside, analysts plainly believe AngioDynamics is more favorable than West Pharmaceutical Services.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
West Pharmaceutical Services	0 Sell rating(s)	2 Hold rating(s)	12 Buy rating(s)	0 Strong Buy rating(s)	2.86
AngioDynamics	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.60

West Pharmaceutical Services has a net margin of 16.98% compared to AngioDynamics' net margin of -10.12%. West Pharmaceutical Services' return on equity of 20.11% beat AngioDynamics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
West Pharmaceutical Services	16.98%	20.11%	14.83%
AngioDynamics	-10.12%	-4.43%	-2.89%

West Pharmaceutical Services has a beta of 1.13, meaning that its share price is 13% more volatile than the broader market. Comparatively, AngioDynamics has a beta of 0.3, meaning that its share price is 70% less volatile than the broader market.

In the previous week, AngioDynamics had 26 more articles in the media than West Pharmaceutical Services. MarketBeat recorded 33 mentions for AngioDynamics and 7 mentions for West Pharmaceutical Services. West Pharmaceutical Services' average media sentiment score of 0.65 beat AngioDynamics' score of 0.38 indicating that West Pharmaceutical Services is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
West Pharmaceutical Services	1 Very Positive mention(s)	4 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
AngioDynamics	6 Very Positive mention(s)	3 Positive mention(s)	15 Neutral mention(s)	4 Negative mention(s)	0 Very Negative mention(s)	Neutral

93.9% of West Pharmaceutical Services shares are held by institutional investors. Comparatively, 89.4% of AngioDynamics shares are held by institutional investors. 0.6% of West Pharmaceutical Services shares are held by company insiders. Comparatively, 6.0% of AngioDynamics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

West Pharmaceutical Services has higher revenue and earnings than AngioDynamics. AngioDynamics is trading at a lower price-to-earnings ratio than West Pharmaceutical Services, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
West Pharmaceutical Services	$3.07B	8.38	$493.70M	$7.81	46.87
AngioDynamics	$320.17M	1.51	-$36.74M	-$0.78	N/A

Summary

West Pharmaceutical Services beats AngioDynamics on 13 of the 17 factors compared between the two stocks.

How does AngioDynamics compare to Butterfly Network?

Butterfly Network (NYSE:BFLY) and AngioDynamics (NASDAQ:ANGO) are both healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their valuation, media sentiment, earnings, profitability, analyst recommendations, risk, institutional ownership and dividends.

AngioDynamics has a net margin of -10.12% compared to Butterfly Network's net margin of -66.74%. AngioDynamics' return on equity of -4.43% beat Butterfly Network's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Butterfly Network	-66.74%	-33.99%	-22.96%
AngioDynamics	-10.12%	-4.43%	-2.89%

Butterfly Network currently has a consensus target price of $8.54, suggesting a potential upside of 3.35%. AngioDynamics has a consensus target price of $19.50, suggesting a potential upside of 69.27%. Given AngioDynamics' higher probable upside, analysts clearly believe AngioDynamics is more favorable than Butterfly Network.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Butterfly Network	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.71
AngioDynamics	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.60

In the previous week, AngioDynamics had 13 more articles in the media than Butterfly Network. MarketBeat recorded 33 mentions for AngioDynamics and 20 mentions for Butterfly Network. AngioDynamics' average media sentiment score of 0.38 beat Butterfly Network's score of 0.27 indicating that AngioDynamics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Butterfly Network	6 Very Positive mention(s)	1 Positive mention(s)	10 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
AngioDynamics	6 Very Positive mention(s)	3 Positive mention(s)	15 Neutral mention(s)	4 Negative mention(s)	0 Very Negative mention(s)	Neutral

Butterfly Network has a beta of 2.04, meaning that its stock price is 104% more volatile than the broader market. Comparatively, AngioDynamics has a beta of 0.3, meaning that its stock price is 70% less volatile than the broader market.

37.9% of Butterfly Network shares are owned by institutional investors. Comparatively, 89.4% of AngioDynamics shares are owned by institutional investors. 22.0% of Butterfly Network shares are owned by company insiders. Comparatively, 6.0% of AngioDynamics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

AngioDynamics has higher revenue and earnings than Butterfly Network. Butterfly Network is trading at a lower price-to-earnings ratio than AngioDynamics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Butterfly Network	$97.61M	22.55	-$77.06M	-$0.29	N/A
AngioDynamics	$320.17M	1.51	-$36.74M	-$0.78	N/A

Summary

AngioDynamics beats Butterfly Network on 10 of the 16 factors compared between the two stocks.

How does AngioDynamics compare to AxoGen?

AngioDynamics (NASDAQ:ANGO) and AxoGen (NASDAQ:AXGN) are both small-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, dividends, profitability, earnings, media sentiment, institutional ownership, risk and analyst recommendations.

89.4% of AngioDynamics shares are held by institutional investors. Comparatively, 80.3% of AxoGen shares are held by institutional investors. 6.0% of AngioDynamics shares are held by company insiders. Comparatively, 2.4% of AxoGen shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

AngioDynamics currently has a consensus price target of $19.50, suggesting a potential upside of 69.27%. AxoGen has a consensus price target of $51.70, suggesting a potential upside of 43.09%. Given AngioDynamics' higher probable upside, analysts clearly believe AngioDynamics is more favorable than AxoGen.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
AngioDynamics	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.60
AxoGen	1 Sell rating(s)	2 Hold rating(s)	10 Buy rating(s)	1 Strong Buy rating(s)	2.79

AxoGen has lower revenue, but higher earnings than AngioDynamics. AxoGen is trading at a lower price-to-earnings ratio than AngioDynamics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
AngioDynamics	$320.17M	1.51	-$36.74M	-$0.78	N/A
AxoGen	$225.21M	8.62	-$15.70M	-$0.68	N/A

AngioDynamics has a net margin of -10.12% compared to AxoGen's net margin of -13.36%. AngioDynamics' return on equity of -4.43% beat AxoGen's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
AngioDynamics	-10.12%	-4.43%	-2.89%
AxoGen	-13.36%	-8.90%	-6.47%

In the previous week, AngioDynamics had 22 more articles in the media than AxoGen. MarketBeat recorded 33 mentions for AngioDynamics and 11 mentions for AxoGen. AngioDynamics' average media sentiment score of 0.38 beat AxoGen's score of 0.35 indicating that AngioDynamics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
AngioDynamics	6 Very Positive mention(s)	3 Positive mention(s)	15 Neutral mention(s)	4 Negative mention(s)	0 Very Negative mention(s)	Neutral
AxoGen	1 Very Positive mention(s)	1 Positive mention(s)	6 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

AngioDynamics has a beta of 0.3, meaning that its stock price is 70% less volatile than the broader market. Comparatively, AxoGen has a beta of 1.17, meaning that its stock price is 17% more volatile than the broader market.

Summary

AngioDynamics beats AxoGen on 10 of the 16 factors compared between the two stocks.

How does AngioDynamics compare to Inspire Medical Systems?

Inspire Medical Systems (NYSE:INSP) and AngioDynamics (NASDAQ:ANGO) are both small-cap healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, dividends, media sentiment, profitability, analyst recommendations, valuation, earnings and risk.

Inspire Medical Systems has higher revenue and earnings than AngioDynamics. AngioDynamics is trading at a lower price-to-earnings ratio than Inspire Medical Systems, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Inspire Medical Systems	$911.98M	2.18	$145.42M	$4.62	14.91
AngioDynamics	$320.17M	1.51	-$36.74M	-$0.78	N/A

94.9% of Inspire Medical Systems shares are owned by institutional investors. Comparatively, 89.4% of AngioDynamics shares are owned by institutional investors. 2.2% of Inspire Medical Systems shares are owned by company insiders. Comparatively, 6.0% of AngioDynamics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Inspire Medical Systems has a net margin of 15.03% compared to AngioDynamics' net margin of -10.12%. Inspire Medical Systems' return on equity of 8.64% beat AngioDynamics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Inspire Medical Systems	15.03%	8.64%	7.45%
AngioDynamics	-10.12%	-4.43%	-2.89%

Inspire Medical Systems presently has a consensus price target of $67.29, suggesting a potential downside of 2.33%. AngioDynamics has a consensus price target of $19.50, suggesting a potential upside of 69.27%. Given AngioDynamics' stronger consensus rating and higher probable upside, analysts clearly believe AngioDynamics is more favorable than Inspire Medical Systems.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Inspire Medical Systems	4 Sell rating(s)	12 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.05
AngioDynamics	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.60

In the previous week, AngioDynamics had 24 more articles in the media than Inspire Medical Systems. MarketBeat recorded 33 mentions for AngioDynamics and 9 mentions for Inspire Medical Systems. Inspire Medical Systems' average media sentiment score of 1.24 beat AngioDynamics' score of 0.38 indicating that Inspire Medical Systems is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Inspire Medical Systems	7 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
AngioDynamics	6 Very Positive mention(s)	3 Positive mention(s)	15 Neutral mention(s)	4 Negative mention(s)	0 Very Negative mention(s)	Neutral

Inspire Medical Systems has a beta of 0.73, suggesting that its stock price is 27% less volatile than the broader market. Comparatively, AngioDynamics has a beta of 0.3, suggesting that its stock price is 70% less volatile than the broader market.

Summary

Inspire Medical Systems beats AngioDynamics on 12 of the 16 factors compared between the two stocks.

Get AngioDynamics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ANGO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ANGO vs. The Competition

Export

Metric	AngioDynamics	Healthcare Equipment & Supplies Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$472.27M	$5.44B	$7.16B	$13.21B
Dividend Yield	N/A	1.78%	2.53%	16.37%
P/E Ratio	-14.77	25.57	274.15	26.16
Price / Sales	1.51	83.25	635.97	113.01
Price / Cash	35.90	31.87	76.38	53.09
Price / Book	2.79	5.93	11.21	6.34
Net Income	-$36.74M	$146.18M	$3.50B	$381.90M
7 Day Performance	-23.76%	-0.38%	-0.90%	-1.41%
1 Month Performance	-24.41%	-2.02%	-4.44%	-3.48%
1 Year Performance	4.73%	5.08%	6.96%	1.16%

AngioDynamics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ANGO AngioDynamics	3.8803 of 5 stars	$11.52 +2.6%	$19.50 +69.3%	+3.4%	$472.27M	$320.17M	N/A	632	Trending News Earnings Report Analyst Forecast High Trading Volume
TMO Thermo Fisher Scientific	4.1185 of 5 stars	$673.78 -0.7%	$628.78 -6.7%	+23.1%	$249.60B	$44.56B	36.31	125,000	News Coverage Analyst Forecast
WST West Pharmaceutical Services	4.0507 of 5 stars	$371.56 -1.1%	$382.00 +2.8%	+38.9%	$26.18B	$3.07B	47.63	10,800	Analyst Forecast
BFLY Butterfly Network	2.4236 of 5 stars	$9.51 +3.9%	$8.54 -10.1%	+221.0%	$2.54B	$97.61M	N/A	220	News Coverage Insider Trade Gap Up
AXGN AxoGen	3.26 of 5 stars	$43.24 -0.3%	$52.11 +20.5%	+120.0%	$2.33B	$225.21M	N/A	622	Analyst Upgrade

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ANGO) was last updated on 10/10/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

AngioDynamics (ANGO) Competitors

ANGO vs. TMO, WST, BFLY, AXGN, and INSP

How does AngioDynamics compare to Thermo Fisher Scientific?

Summary

How does AngioDynamics compare to West Pharmaceutical Services?

Summary

How does AngioDynamics compare to Butterfly Network?

Summary

How does AngioDynamics compare to AxoGen?

Summary

How does AngioDynamics compare to Inspire Medical Systems?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ANGO vs. The Competition

AngioDynamics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

AngioDynamics (ANGO) Competitors

ANGO vs. TMO, WST, BFLY, AXGN, and INSP

How does AngioDynamics compare to Thermo Fisher Scientific?

Which has better valuation and earnings, ANGO or TMO?

Do insiders & institutionals have more ownership in ANGO or TMO?

Do analysts prefer ANGO or TMO?

Is ANGO or TMO more profitable?

Does the media favor ANGO or TMO?

Which has more risk and volatility, ANGO or TMO?

Summary

How does AngioDynamics compare to West Pharmaceutical Services?

Do analysts recommend WST or ANGO?

Is WST or ANGO more profitable?

Which has more risk & volatility, WST or ANGO?

Does the media prefer WST or ANGO?

Do institutionals and insiders hold more shares of WST or ANGO?

Which has better valuation & earnings, WST or ANGO?

Summary

How does AngioDynamics compare to Butterfly Network?

Is BFLY or ANGO more profitable?

Do analysts recommend BFLY or ANGO?

Does the media prefer BFLY or ANGO?

Which has more risk and volatility, BFLY or ANGO?

Do insiders & institutionals hold more shares of BFLY or ANGO?

Which has stronger valuation and earnings, BFLY or ANGO?

Summary

How does AngioDynamics compare to AxoGen?

Do institutionals and insiders hold more shares of ANGO or AXGN?

Do analysts rate ANGO or AXGN?

Which has stronger valuation & earnings, ANGO or AXGN?

Is ANGO or AXGN more profitable?

Does the media favor ANGO or AXGN?

Which has more risk & volatility, ANGO or AXGN?

Summary

How does AngioDynamics compare to Inspire Medical Systems?

Which has higher valuation and earnings, INSP or ANGO?

Do institutionals & insiders have more ownership in INSP or ANGO?

Is INSP or ANGO more profitable?

Do analysts prefer INSP or ANGO?

Does the media prefer INSP or ANGO?

Which has more risk & volatility, INSP or ANGO?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ANGO vs. The Competition

AngioDynamics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools